1 479

Cited 1 times in

Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance

DC FieldValueLanguage
dc.contributor.author구자승-
dc.contributor.author김승일-
dc.contributor.author김주항-
dc.contributor.author노재경-
dc.contributor.author문용화-
dc.contributor.author박병우-
dc.contributor.author박세호-
dc.contributor.author손주혁-
dc.contributor.author장현-
dc.contributor.author정현철-
dc.contributor.author최혜진-
dc.date.accessioned2015-04-23T17:06:48Z-
dc.date.available2015-04-23T17:06:48Z-
dc.date.issued2010-
dc.identifier.issn0344-5704-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/101844-
dc.description.abstractBACKGROUND: We evaluated the efficacy and tolerability of combined paclitaxel and ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer (MBC). METHODS: Patients received paclitaxel (175 mg/m(2) i.v. in a 3-h infusion) on day 1 and ifosfamide (1.5 g/m(2) i.v. in a 15-min infusion) on days 1-3, every 3 weeks for a maximum of nine cycles. The tumor response was assessed every two cycles. RESULTS: We enrolled 34 patients with a median age of 50 years. Thirty patients had visceral metastases. Anthracycline- and docetaxel-based chemotherapy had previously been administered to 18/13 and 13/21 patients, respectively, in (neo)adjuvant/metastatic settings. Three patients had not previously received anthracycline due to abnormal cardiac functions. A total of 174 cycles of chemotherapy were delivered with a median of six cycles. The response rate under the intent-to-treat analysis was 23.5% (all partial responses) with a median response duration of 14 months. The disease control rate was 70.6%. The median progression-free and overall survival were 5.9 and 8.5 months, respectively. There was no apparent relationship between activity and prior docetaxel resistance. The incidence of grade III/IV neutropenia was 46.6% (81 of 174 cycles) with febrile neutropenia of only 1.7%. Major grade III/IV non-hematological toxicities included peripheral neuropathy (6 of 34 patients) and infection (4 of 34 patients). There were no treatment-related deaths. CONCLUSION: Paclitaxel combined with ifosfamide was effective and tolerable in anthracycline-/docetaxel-pretreated MBC. Overcoming docetaxel resistance by using paclitaxel in combination with ifosfamide needs to be addressed through further investigation-
dc.description.statementOfResponsibilityopen-
dc.format.extent425~431-
dc.relation.isPartOfCANCER CHEMOTHERAPY AND PHARMACOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAnthracyclines/administration & dosage-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/adverse effects-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHBreast Neoplasms/drug therapy*-
dc.subject.MESHBreast Neoplasms/mortality-
dc.subject.MESHBreast Neoplasms/pathology-
dc.subject.MESHDrug Resistance, Neoplasm-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHIfosfamide/administration & dosage-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Metastasis-
dc.subject.MESHNeutropenia/chemically induced-
dc.subject.MESHPaclitaxel/administration & dosage-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSurvival Rate-
dc.subject.MESHTaxoids/administration & dosage-
dc.subject.MESHTaxoids/pharmacology-
dc.subject.MESHTreatment Outcome-
dc.titlePaclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학)-
dc.contributor.googleauthorYong Wha Moon-
dc.contributor.googleauthorJoo Hyuk Sohn-
dc.contributor.googleauthorHye Jin Choi-
dc.contributor.googleauthorHyun Chang-
dc.contributor.googleauthorByeong-Woo Park-
dc.contributor.googleauthorSeung Il Kim-
dc.contributor.googleauthorSeho Park-
dc.contributor.googleauthorJa Seung Koo-
dc.contributor.googleauthorYong Tai Kim-
dc.contributor.googleauthorJae Kyung Roh-
dc.contributor.googleauthorHyun Cheol Chung-
dc.contributor.googleauthorJoo-Hang Kim-
dc.identifier.doi10.1007/s00280-009-1176-5-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00198-
dc.contributor.localIdA00658-
dc.contributor.localIdA00945-
dc.contributor.localIdA01290-
dc.contributor.localIdA01370-
dc.contributor.localIdA01475-
dc.contributor.localIdA01524-
dc.contributor.localIdA01995-
dc.contributor.localIdA03491-
dc.contributor.localIdA03773-
dc.contributor.localIdA04219-
dc.relation.journalcodeJ00437-
dc.identifier.eissn1432-0843-
dc.identifier.pmid20012956-
dc.identifier.urlhttp://link.springer.com/article/10.1007%2Fs00280-009-1176-5-
dc.subject.keywordAnthracyclines-
dc.subject.keywordBreast cancer-
dc.subject.keywordDocetaxel-
dc.subject.keywordPaclitaxel-
dc.subject.keywordIfosfamide-
dc.contributor.alternativeNameKoo, Ja Seung-
dc.contributor.alternativeNameKim, Seung Il-
dc.contributor.alternativeNameKim, Joo Hang-
dc.contributor.alternativeNameRoh, Jae Kyung-
dc.contributor.alternativeNameMoon, Yong Wha-
dc.contributor.alternativeNamePark, Byeong Woo-
dc.contributor.alternativeNamePark, Se Ho-
dc.contributor.alternativeNameSohn, Joo Hyuk-
dc.contributor.alternativeNameChang, Hyun-
dc.contributor.alternativeNameChung, Hyun Cheol-
dc.contributor.alternativeNameChoi, Hye Jin-
dc.contributor.affiliatedAuthorKoo, Ja Seung-
dc.contributor.affiliatedAuthorKim, Seung Il-
dc.contributor.affiliatedAuthorKim, Joo Hang-
dc.contributor.affiliatedAuthorRoh, Jae Kyung-
dc.contributor.affiliatedAuthorMoon, Yong Wha-
dc.contributor.affiliatedAuthorPark, Byeong Woo-
dc.contributor.affiliatedAuthorPark, Se Ho-
dc.contributor.affiliatedAuthorSohn, Joo Hyuk-
dc.contributor.affiliatedAuthorChang, Hyun-
dc.contributor.affiliatedAuthorChung, Hyun Cheol-
dc.contributor.affiliatedAuthorChoi, Hye Jin-
dc.contributor.affiliatedAuthor구자승-
dc.citation.volume66-
dc.citation.number3-
dc.citation.startPage425-
dc.citation.endPage431-
dc.identifier.bibliographicCitationCANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.66(3) : 425-431, 2010-
dc.identifier.rimsid54647-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.